Related Experiment Video
Updated: Jun 9, 2026
09:46
An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina
Published on: July 15, 2025
Neuroprotection in glaucoma - Is there a future role?
Abeir Baltmr1, James Duggan, Shereen Nizari
1Glaucoma and Retinal Neurodegeneration Research Group, Visual Neurosciences Department, University College London Institute of Ophthalmology, Bath Street, London EC1V 9EL, United Kingdom.
Experimental Eye Research
|August 31, 2010
Summary
Glaucoma treatment needs new approaches beyond lowering eye pressure to protect retinal ganglion cells (RGCs). This review explores neuroprotective strategies targeting RGCs to prevent vision loss.
Area of Science:
- Ophthalmology
- Neuroscience
- Cell Biology
Background:
- Glaucoma is a leading cause of irreversible blindness globally.
- Current treatments focus on intraocular pressure (IOP) reduction, which has indirect effects and limited success in preventing retinal ganglion cell (RGC) loss.
- There is a critical need for therapies that directly protect RGCs, independent of IOP.
- Multiple mechanisms, including excitotoxicity, protein misfolding, mitochondrial dysfunction, oxidative stress, inflammation, and neurotrophin deprivation, contribute to RGC apoptosis in glaucoma.
Purpose of the Study:
- To summarize the mechanisms underlying glaucomatous disease.
- To highlight the rationale for neuroprotection in glaucoma management.
- To review current and potential neuroprotective strategies targeting RGCs.
Main Methods:
- Literature review of mechanisms involved in glaucomatous disease.
- Analysis of neuroprotective drug efficacy in animal models.
- Evaluation of therapeutic strategies targeting RGCs from preclinical to clinical stages.
Main Results:
- Several pathways initiate RGC apoptosis in glaucoma.
- Various drugs have demonstrated neuroprotective effects in glaucoma animal models.
- Neuroprotection offers a promising therapeutic avenue independent of IOP reduction.
Conclusions:
- Directly targeting RGCs offers a promising alternative to IOP reduction for glaucoma management.
- Understanding the molecular mechanisms of RGC death is crucial for developing effective neuroprotective therapies.
- Translating laboratory findings into clinical applications is essential for advancing glaucoma treatment.
Related Concept Videos
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...